India, Nov. 9 -- image credit- freepik

Mumbai-based BDR Pharma and PAG (a leading Asia-Pacific-focused alternative investment firm) have announced that BDR Pharma will acquire a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries from its existing shareholders, led by PAG.

The acquisition aligns with BDR's growth priorities across oncology, critical care and women's healthcare, while creating opportunities to expand its product offerings in international markets.

A key strategic rationale for the acquisition is the addition of complementary capabilities across thyroid products, female sex hormone products and general pharmaceutical products. o3 Capital acted as the exclusive financial advi...